Table 4.
Treatment regimens
| Treatment modality | Therapeutic regimen | n (%) |
|---|---|---|
| Neoadjuvant | mFOLFIRINOX | 14 |
| 18 participants received 33 therapeutic regimens* | Gemcitabine-based | 4 |
| Chemotherapy followed by chemo-radiation therapy | 11 | |
| Clinical trial | 4 | |
| Adjuvant | Gemcitabine-based | 47 |
| 49 participants received 70 therapeutic regimens* | Chemotherapy followed by chemo-radiation therapy | 14 |
| Clinical trial | 7 | |
| mFOLFIRINOX | 2 | |
| Perioperative radiation protocol (gray/fractions); N25 (%) | 50.4 Gy/28 Fx | 18 (72.0) |
| 33 Gy/5–10 Fx | 4 (16.0) | |
| Unknown | 3 (12.0) | |
| First-line treatment; N36 (%) | Gemcitabine-nab-paclitaxel | 14 (38.8) |
| mFOLFIRINOX | 8 (22.2) | |
| CAPOX | 7 (19.4) | |
| Chemo-radiation therapy followed by chemotherapy | 3 (8.3) | |
| FOLFOX | 2 (5.5) | |
| Nanoliposomal irinotecan-based | 1 (2.7) | |
| FOLFIRI | 1 (2.7) | |
| Second-line treatment N16 (%) | Gemcitabine-nab-paclitaxel | 6 (37.5) |
| CAPOX | 4 (25.0) | |
| Nanoliposomal irinotecan-based | 3 (18.7) | |
| mFOLFIRINOX | 2(12.5) | |
| Chemo-radiation therapy followed by chemotherapy | 1 (6.2) | |
| Time to surgery from diagnosis (weeks) | 5.3 | |
| Time to neoadjuvant from diagnos is (weeks) | 4.7 | |
| Time to adjuvant from surgery (weeks) | 8.9 |
*
, patients may appear in multiple treatment regimens on the neoadjuvant and adjuvant treatment modalities.
mFOLFIRINOX, modified FOLinic acid-Fluorouracil-IRINotecan-OXaliplatin; CAPOX, CAPecitabine-Oxaliplatin; FOLFOX, FOLinic acid-Fluororuracil-OXaliplatin; FOLFIRI, FOLinic acid, Fluorouracil, IRInotecan.